文献速递外周动脉疾病

阿司匹林单药与其他抗血小板方案在外周动脉疾病中疗效的系统评价

A systematic review of the efficacy of aspirin monotherapy versus other antiplatelet therapy regimens in peripheral arterial disease.
PubMed 文献 · J Vasc Surg · 2018-01-01

该系统评价纳入14项研究(其中10项为随机对照试验),比较外周动脉疾病血运重建后双联抗血小板治疗与单联抗血小板治疗。结果显示双联治疗降低主要不良心脏事件(RR 0.79)、主要不良心脑血管事件及死亡(RR 0.57),但中度出血增加,大出血相似;双联治疗最佳疗程尚待随机对照试验研究。

要点

  • 双联抗血小板治疗较单联降低主要不良心脏事件(RR 0.79,95%CI 0.68-0.91,P=0.002)。
  • 双联治疗增加中度出血,大出血无显著差异(RR 0.98,95%CI 0.68-1.41,P=0.92)。

核心结论

  • 双联抗血小板治疗似乎有助于预防外周动脉疾病血运重建后的并发症,包括干预的血栓性失败。
  • 但研究中双联抗血小板治疗疗程异质,提示需要额外数据以确定外周动脉疾病患者中双联抗血小板治疗的最佳使用。

研究设计与样本

  • 系统评价,检索两个数据库,纳入14项研究,其中10项为随机对照试验。
  • 纳入研究包括使用静脉或人工血管旁路、血管内操作、下肢动脉诊断性造影及高危因素患者。
  • 随机对照试验总体偏倚风险为低至中等,非随机研究为中等至高度偏倚风险。

主要发现

  • 与单联抗血小板治疗相比,双联抗血小板治疗降低主要不良心脏事件(RR 0.79,95%CI 0.68-0.91,P=0.002)。
  • 双联抗血小板治疗组主要不良肢体事件和靶病变血运重建(RR 0.70,95%CI 0.49-1.01,P=0.06)也降低。
  • 双联抗血小板治疗组中度出血率增加,而大出血率两组相似(RR 0.98,95%CI 0.68-1.41,P=0.92)。
  • 双联抗血小板治疗疗程对外周动脉疾病患者血运重建结局的影响尚未在随机对照试验中研究。

局限性

  • 双联抗血小板治疗疗程在研究间存在异质性。
  • 需要额外数据以确定外周动脉疾病患者中双联抗血小板治疗的最佳使用。
  • 双联抗血小板治疗疗程对外周动脉疾病患者血运重建结局的影响尚未在随机对照试验中研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dual antiplatelet therapy (DAPT) usually refers to the administration of aspirin plus a platelet P2Y12 receptor blocker. This combination is commonly prescribed after revascularization procedures in patients with peripheral arterial disease (PAD) to prevent failure of the intervention. However, there is not a consensus among peripheral vascular specialists regarding whether the optimal treatment regimen for their patients is mono antiplatelet therapy (MAPT) or DAPT. Furthermore, there is no consensus regarding the optimal duration of DAPT. This study was undertaken to systematically and critically review the evidence for the use of DAPT after revascularization in PAD, hypothesizing that longer durations of DAPT will result in decreased rates of major adverse cardiac events, major adverse limb events, and mortality, without a significant increase in severe bleeding episodes compared with MAPT or shorter durations of DAPT. METHODS: A systematic search strategy encompassing DAPT and PAD was deployed in two databases. Studies including arterial bypasses using venous or prosthetic conduits, endovascular procedures, diagnostic angiography of lower extremity arteries, and patients with high risk factors were included. RESULTS: We included 14 studies, 10 of which were randomized controlled trials (RCTs). The overall risk of bias for the RCTs ranged from low to moderate, whereas nonrandomized studies had moderate to high risk of bias. The results of this review suggest that use of DAPT in patients with PAD reduces rates of major adverse cardiac events (risk ratio [RR], 0.79; 95% confidence interval [CI], 0.68-0.91; P = .002), major adverse cardiac and cerebrovascular events, and mortality (RR, 0.57; 95% CI, 0.45-0.72; P < .00,001) compared with those of patients treated with MAPT. Lower extremity-specific end points, such as major adverse limb events and target lesion revascularization (RR, 0.70; 95% CI, 0.49-1.01; P = .06) were also decreased in the DAPT cohort. Rates of moderate bleeding, however, were increased in those treated with DAPT, whereas rates of major bleeding (RR, 0.98; 95% CI, 0.68-1.41; P = .92) remained similar in both treatment groups. The effects of DAPT duration on outcomes of revascularization in patients with PAD have yet to be studied in an RCT. CONCLUSIONS: DAPT appears to be beneficial for preventing complications after revascularization in PAD, including thrombotic failure of the intervention. However, the durations of DAPT use in these studies are heterogeneous, suggesting that additional data are needed to determine the optimal use of DAPT in PAD patients.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Beiswenger AC, Jo A, Harth K, et al. A systematic review of the efficacy of aspirin monotherapy versus other antiplatelet therapy regimens in peripheral arterial disease. J Vasc Surg. 2018. PMID: 29801560. doi:10.1016/j.jvs.2018.02.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。